Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891954 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL1867284 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL872735 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL573930 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL17891961 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL27919918 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL17891951 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL3504225 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL17891959 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH | |
| SCHEMBL4316279 | 1.00 | NAAA (0.64) | NAAANPSR1RAD52DGKAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583177-A1 | METHOD OF MANUFACTURING ELECTRODE, COMPOSITE ELECTRODE, ELECTROCHEMICAL ELEMENT, AND APPARATUS FOR MANUFACTURING ELECTRODE | Ricoh Company, Ltd. (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4362128-A1 | LIQUID COMPOSITION, METHOD FOR PRODUCING LIQUID COMPOSITION, ELECTRODE, ELECTRODE PRODUCTION APPARATUS, AND METHOD FOR PRODUCING ELECTRODE | Ricoh Company, Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210322575-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | NAAA 3773/4885NPSR1 1123/4885RAD52 2211/4885 |
| US-20210322575-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | PHOSPHO1, PLIN3, CETP | NAAA 572/4885NPSR1 2389/4885RAD52 2680/4885 |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | LNPEP, SLC7A1, APLNR | NAAA 1292/4885NPSR1 1458/4885RAD52 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.